Verhalten von Fibroblasten aus Nasenpolypen in Zellkultur nach Applikation üblicher Rhinologika und unüblicher Medikamente unterschiedlicher Wirkstoffgruppen

Zusammenfassung

Hintergrund: Nasenpolypen werden chirurgisch oder medikamentös therapiert, ohne dass häufig eine dauerhafte Remission erreichbar ist. Im Rahmen der Polypengenese spielen Fibroblasten und deren Proliferation ebenfalls eine Rolle. Daher wurde der Einfluss von 12 Medikamenten auf ex vivo kultivierte Fibroblasten aus Nasenpolypen untersucht.

Methode: Polypen wurden unmittelbar nach OP enzymatisch aufgeschlossen, die Zellen in serumhaltigem Medium kultiviert und flowzytometrisch als Fibroblasten identifiziert. Die Versuchsansätze (je 5 - 6 verschiedene Fibroblastenkulturen) mit den entsprechenden Verdünnungen der Medikamente (0,006 -1,333 mg/ml der jeweiligen Wirkstoffe) wurden 4 Tage kultiviert, trypsiniert und ausgezählt.

Ergebnisse: Mometason, Beclomethason, Fluticason, Verapamil und Timolol bewirkten stärkste Reduzierung der Fibroblasten, während die Substanzen Mesazalin, Methylprednisolon und Pentoxifyllin die geringste Wirkung hatten. Prednisolon-21-hydrogensuccinat, Pilocarpin, Piroxicam und Diclofenac zeigten mittlere Wirkung.

Schlussfolgerungen: Fibroblasten aus Nasenpolypen lassen sich mit üblichen Rhinologika und unüblichen Medikamenten stark reduzieren.

Abstract

Background: Nasal polyposis is treated by surgery and/or by medication but in parts without permanent remission. Fibroblasts and their proliferation are involved in the complex mechanism of polyp genesis. Therefore we have analysed the influence of 12 medications on fibroblasts from nasal polyps growing in vitro.

Method: Nasal polyps, obtained during usual surgical procedure, are enzymatically digested and cultured in serum containing media. The growing cells are identified as fibroblasts using flow cytometry with a AS02-FITC antibody (Dianova). The analysis is achieved with 5 - 6 different fibroblast cultures in each medicament tested, mostly using concentrations of the active substance from 0.006 to 1.333 mg/ml. The fibroblasts are cultured 4 days in the presence of active substances or as controls. Finally the cells are trypsinated and counted.

Results: Mometason, Beclomethason, Fluticason, Verapamil and Timolol are the group with the strongest reduction of fibroblasts. Mometason shows a reduction to 6 % of controls at a concentration of 30 µg/ml whereas the reduction at this concentration amounts to 30 - 60 % in the other members of this group. Mesazalin, Methylprednisolone and Pentoxifylline demonstrate the smallest influence; Prednisolon-21-hydrogen-succinate, Pilocarpin, Piroxicam and Diclofenac show an effect on a middle level.

Conclusions: A strong reduction of fibroblasts from nasal polyps in vitro is possible with usual rhinological medicaments but also with unusual substances in this field.

Nasenpolypen - Fibroblasten - Zellkultur - Medikamente - Zytotoxizität - Proliferation

Nasal polyps - fibroblasts - cell culture - drug - cytotoxicity - proliferation

Literatur

• 1 Kirsch J P, White J A. Nasal polyposis.  J La state Med Soc. 1990;  142 11-14
• 2 Rudack C. Untersuchungen zum Entzündungsgeschehen in Nasenpolypen.  Laryngo-Rhino-Otologie. 2002;  81 659-660
• 3 Rudack C, Hauser U, Stoll W. Einfluss von Zytokinen und Fibroblasten auf die Überlebenszeit eosinophiler Granulozyten bei der Polyposis nasi.  Laryngo-Rhino-Otologie. 1999;  78 378-381
• 4 Bachert C, Lange B. Polyposis Nasi.  Allergiemanagment. 1999;  4 27-32
• 5 Bachert C, Wagenmann M, Rudack C, Hopken K, Hillebrandt M, Wang D, van Cauwenberge P. The role of cytokines in infectious sinusitis and nasal polyposis.  Allergy. 1998;  53 2-13
• 6 Weber A, Schröder U H, May A, von Ilberg C, Frömter E. Chloridleitfähigkeit nasaler Fibroblasten von Polyposis-Patienten mit zystischer Fibrose und Patienten ohne zystische Fibrose.  HNO. 1997;  45 695-701
• 7 Wang D, Levasseur-Acker G M, Jankowski R, Kanny G, Moneret-Vautrin D A, Charron D, Lockhart A, Swierczewski E. HLA class II antigens and T lymphocytes in human nasal epithelial cells. Modulation of the HLA class II gene transcripts by gamma interferon.  Clin Exp Allergy. 1997;  27 306-314
• 8 Nonaka M, Pawankar R, Saji F, Yagi T. Effect of roxithromycin on IL-8 synthesis and proliferation of nasal polyp fibroblasts.  Acta Otolaryngol Suppl. 1998;  539 71-75
• 9 Nakagawa T, Yamane H, Nakai Y, Shigeta T, Takashima T, Takeda Z. Comparative assessment of cell proliferation and accumulation of extracellular matrix in nasal polyps.  Acta Otolaryngol Suppl. 1998;  538 205-208
• 10 Umbach B, Hennebach U. Veränderungen im Bindegewebsmetabolismus von Fibroblasten aus Nasenpolypen.  HNO. 1994;  42 344-349
• 11 Larsen P L, Tos M, Kuijpers W, van der Beek J M. The early stages of polyp formation.  Laryngoscope. 1992;  102 670-677
• 12 Johansen L V, Illum P, Kristensen S, Winther L, Petersen S V, Synnerstad P. The effect of budenoside (Rhinocort) in the treatment of small and medium sized nasal polyps.  Clin Otolaryngol. 1993;  18 524-527
• 13 Rhuno J, Anderson B, Denburg J. A double-blind comparision of intranasal budenoside with placebo for nasal popyposis.  J Allergy Clin Immunol. 1990;  86 946-953
• 14 Williams D E, Nguyen K D, Shapourifar-Tehrani S, Kitada S, Lee D A. Effects of timolol, betaxolol, and levobunolol on human tenon’s fibroblasts in tissue culture.  Invest Ophthalmol Vis Sci. 1992;  33 2233-2241
• 15 Cunlife I A, McIntyre C A, Rees R C, Rennie I G. The effect of topical cholinergic medications on human Tenon’s capsule fibroblasts in tissue culture.  Graefes Arch Clin Exp Ophthalmol. 1995;  233 507-512
• 16 Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting H C, Schafer-Korting M. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids.  Skin Pharmacol Appl Skin Physiol. 2000;  13 93-103
• 17 Muhlberg T, Joba W, Spitzweg C, Schworm H D, Heberling H J, Heufelder A E. Interleukin-1 receptor antagonist ribonucleic acid and protein expression by cultured Graves’ and normal orbital fibroblasts is differentially modulated by dexamethasone and irradiation.  J Clin Endocrinol Metab. 2000;  85 734-742
• 18 Hein R, Korting H C, Mehring T. Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro.  Skin Pharmacol. 1994;  7 300-306
• 19 Gormar F E, Bernd A, Holzmann H. The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro.  Arzneimittelforschung. 1990;  40 192-196
• 20 Silvestri M, Sabatini F, Scarso L, Cordone A, Dasic G, Rossi G A. Fluticasone propionate downregulates nasal fibroblast functions involved in airway inflammation and remodeling.  Int Arch Allergy Immunol. 2002;  128 51-58
• 21 Li S, Mawal-Dewan M, Cristofalo V J, Sell C. Enhanced proliferation of human fibroblasts, in the presence of dexamethasone, is accompanied by changes in p21Waf1/Cip1/Sdi1 and the insulin-like growth factor type 1 receptor.  J Cell Physiol. 1998;  177 396-401
• 22 Albrecht M, Janssen M, Konrad L, Renneberg H, Aumuller G. Effects of dexamethasone on proliferation of and fibronectin synthesis by human primary prostatic stromal cells in vitro.  Andrologia. 2002;  34 11-21
• 23 Bruzzese N, Sica G, Iacopino F, Paludetti G, Schiavino D, Nucera E, Scarano E, Patriarca G. Growth inhibition of fibroblasts from nasal polyps and normal skin by lysine acetylsalicylate.  Allergy. 1998;  53 431-434
• 24 Tarpila E, Franzen L, Ghassemifar R, Risto O. The effect of diclofenac (Voltaren) on the contraction of collagen lattices.  Scand J Plast Reconstr Surg Hand Surg. 1997;  31 105-107
• 25 Sun R, Gimbel H V, Liu S, Guo D, Hollenberg M D. Effect of diclofenac sodium and dexamethasone on cultured human Tenon’s capsule fibroblasts.  Ophthalmic Surg Lasers. 1999;  5 382-388
• 26 Nguyen K D, Lee D A. In vitro evaluation of antiproliferative potential of topical cyclooxygenase inhibitors in human Tenon’s fibroblasts.  Exp Eye Res. 1993;  57 97-105
• 27 Mattey D L, Evans E, Dawes P T. The effects of Tenidap on cytokine induced proliferation of human synovial fibroblasts in vitro.  Ann Rheum Dis. 1994;  53 250-255
• 28 Zeitler H, Ko Y, Glodny B, Totzke G, Appenheimer M, Sachinidis A, Vetter H. Cell-cycle arrest in G0/G1 phase of growth factor-induced endothelial cell proliferation by various calcium channel blockers.  Cancer Detect Prev. 1997;  21 332-339
• 29 Kang Y, Lee D A, Higginbotham E J. In vitro evaluation of antiproliferative potential of calcium channel blockers in human Tenon’s fibroblasts.  Exp Eye Res. 1997;  64 913-925
• 30 Anderson M S, Shankey T V, Lubrano T, Mulhall J P. Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents.  Int J Impot Res. 2000;  12(Suppl 3) 25-31
• 31 Chidiac P, Hebert T E, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of beta-adrenergic antagonists.  Mol Pharmacol. 1994;  45 490-499
• 32 Hussain S S, Al-Dakan A A, Aboul-Enein H Y, Hannan M A. DNA strand breaks and mutations caused by penbutolol, a beta blocker.  Mutat Res. 1988;  204 675-682
• 33 Wu K Y, Hong S J, Wang H Z. Effects of pilocarpine and other antiglaucoma drugs on cultured human Tenon’s fibroblast cells.  J Ocul Pharmacol Ther. 1997;  13 13-21
• 34 Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Muller G A. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts.  Nephrol Dial Transplant. 2000;  15 1535-1546
• 35 Desmouliere A, Xu G, Costa A M, Yousef I M, Gabbiani G, Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells.  J Hepatol. 1999;  30 621-631
• 36 Hewitson T D, Martic M, Kelynack K J, Pedagogos E, Becker G J. Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion.  Am J Nephrol. 2000;  20 82-88